Endocrine and Bone Complications in β-thalassemia Intermedia: Current Understanding and Treatment

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2015 Apr 3

PMID 25834825

Citations 13

Authors

Adlette Inati

MohammadHassan A Noureldine

Anthony Mansour

Hussein A Abbas

Affiliations

Soon will be listed here.

Abstract

Thalassemia intermedia (TI), also known as nontransfusion dependent thalassemia (NTDT), is a type of thalassemia where affected patients do not require lifelong regular transfusions for survival but may require occasional or even frequent transfusions in certain clinical settings and for defined periods of time. NTDT encompasses three distinct clinical forms: β-thalassemia intermedia (β-TI), Hb E/β-thalassemia, and α-thalassemia intermedia (Hb H disease). Over the past decade, our understanding of the molecular features, pathophysiology, and complications of NTDT particularly β-TI has increased tremendously but data on optimal treatment of disease and its various complications are still lacking. In this paper, we shall review a group of commonly encountered complications in β-TI, mainly endocrine and bone complications.

Citing Articles

A retrospective study of glucose homeostasis, insulin secretion, sensitivity/resistance in non- transfusion-dependent β-thalassemia patients (NTD- β Thal): reduced β-cell secretion rather than insulin resistance seems to be the dominant defect for....

De Sanctis V, Daar S, Soliman A, Tzoulis P, Yassin M, Kattamis C Acta Biomed. 2023; 94(6):e2023262.

PMID: 38054678 PMC: 10734240. DOI: 10.23750/abm.v94i6.15001.

Endocrine disorders in Beta-Thalassemia major patients at a Tertiary Care Hospital.

Malik S, Kanwal S, Javed J, Hidayat W, Ghaffar T, Aamir A Pak J Med Sci. 2023; 39(3):726-731.

PMID: 37250540 PMC: 10214794. DOI: 10.12669/pjms.39.3.6837.

Non-Transfusion-Dependent Thalassemia: A Panoramic Review.

Shash H Medicina (Kaunas). 2022; 58(10).

PMID: 36295656 PMC: 9608723. DOI: 10.3390/medicina58101496.

Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies.

Casale M, Baldini M, Del Monte P, Gigante A, Grandone A, Origa R J Clin Med. 2022; 11(7).

PMID: 35407442 PMC: 8999784. DOI: 10.3390/jcm11071826.

Luspatercept: A Gigantic Step in the Treatment of Transfusion-Dependent β-Thalassemia Patients-a Quick Review.

Darvishi-Khezri H, Karami H Adv Ther. 2021; 38(4):1732-1745.

PMID: 33661441 DOI: 10.1007/s12325-021-01663-4.

References

Nassar A, Usta I, Taher A . Beta-thalassemia intermedia and pregnancy: should we anticoagulate?. J Thromb Haemost. 2006; 4(6):1413-4. DOI: 10.1111/j.1538-7836.2006.01912.x. View

Gamberini M, De Sanctis V, Gilli G . Hypogonadism, diabetes mellitus, hypothyroidism, hypoparathyroidism: incidence and prevalence related to iron overload and chelation therapy in patients with thalassaemia major followed from 1980 to 2007 in the Ferrara Centre. Pediatr Endocrinol Rev. 2009; 6 Suppl 1:158-69. View

Vigna G, Tonolo G, Brizzi P, Ciccarese M, Donega P, Maioli M . Plasma lipoprotein composition, apolipoprotein(a) concentration and isoforms in beta-thalassemia. Atherosclerosis. 1997; 131(1):127-33. DOI: 10.1016/s0021-9150(97)06095-4. View

Pintor C, Loche S, Faedda A, Puggioni R, Nurchi A, Fanni V . Sexual maturation and adrenal function in girls with thalassemia. J Endocrinol Invest. 1984; 7(3):181-4. DOI: 10.1007/BF03348419. View

Origa R, Galanello R, Ganz T, Giagu N, Maccioni L, Faa G . Liver iron concentrations and urinary hepcidin in beta-thalassemia. Haematologica. 2007; 92(5):583-8. DOI: 10.3324/haematol.10842. View

Musallam K, Cappellini M, Taher A . Iron overload in β-thalassemia intermedia: an emerging concern. Curr Opin Hematol. 2013; 20(3):187-92. DOI: 10.1097/MOH.0b013e32835f5a5c. View

Haddad A, Tyan P, Radwan A, Mallat N, Taher A . β-Thalassemia Intermedia: A Bird's-Eye View. Turk J Haematol. 2014; 31(1):5-16. PMC: 3996637. DOI: 10.4274/Tjh.2014.0032. View

De Sanctis V, Eleftheriou A, Malaventura C . Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. 2006; 2 Suppl 2:249-55. View

Voskaridou E, Terpos E . New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol. 2004; 127(2):127-39. DOI: 10.1111/j.1365-2141.2004.05143.x. View

10.

Brumsen C, Papapoulos S, Lips P, Geelhoed-Duijvestijn P, Hamdy N, Landman J . Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res. 2002; 17(6):1057-64. DOI: 10.1359/jbmr.2002.17.6.1057. View

11.

Papadimas J, Goulis D, Mandala E, Georgiadis G, Zournatzi V, Tarlatzis B . beta-thalassemia and gonadal axis: a cross-sectional, clinical study in a Greek population. Hormones (Athens). 2006; 1(3):179-87. DOI: 10.14310/horm.2002.1166. View

12.

Vogiatzi M, Macklin E, Fung E, Vichinsky E, Olivieri N, Kwiatkowski J . Prevalence of fractures among the Thalassemia syndromes in North America. Bone. 2005; 38(4):571-5. PMC: 4594870. DOI: 10.1016/j.bone.2005.10.001. View

13.

Dresner Pollack R, RACHMILEWITZ E, Blumenfeld A, Idelson M, Goldfarb A . Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol. 2000; 111(3):902-7. View

14.

Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C . Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlled trial. Haematologica. 2006; 91(9):1193-202. View

15.

Taher A, Musallam K, Cappellini M, Weatherall D . Optimal management of β thalassaemia intermedia. Br J Haematol. 2011; 152(5):512-23. DOI: 10.1111/j.1365-2141.2010.08486.x. View

16.

Huang K, Mittelman S, Coates T, Geffner M, Wood J . A significant proportion of thalassemia major patients have adrenal insufficiency detectable on provocative testing. J Pediatr Hematol Oncol. 2014; 37(1):54-9. PMC: 4393555. DOI: 10.1097/MPH.0000000000000199. View

17.

Taher A, Ismaeel H, Cappellini M . Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006; 37(1):12-20. DOI: 10.1016/j.bcmd.2006.04.005. View

18.

Altamentova S, Marva E, Shaklai N . Oxidative interaction of unpaired hemoglobin chains with lipids and proteins: a key for modified serum lipoproteins in thalassemia. Arch Biochem Biophys. 1997; 345(1):39-46. DOI: 10.1006/abbi.1997.0224. View

19.

Raje N, Vallet S . Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther. 2010; 12(5):586-97. View

20.

Prabhakar S, Chopra J, Khosla V, Dash S, Banerjee A . Spinal cord compression in homozygous beta thalassaemia. Surg Neurol. 1980; 13(5):351-4. View